KRAS Drugs Wipe Out Precancerous Pancreatic Lesions in Groundbreaking Mouse Study

A New Frontier in Cancer Prevention

Scientists at the University of Pennsylvania have demonstrated that experimental drugs targeting the KRAS gene can wipe out microscopic precancerous growths in the pancreas, preventing them from developing into one of the deadliest cancers known to medicine. The study, published in Science on March 12, marks the first proof-of-concept for medical cancer interception in pancreatic cancer.

The Challenge of Pancreatic Cancer

Pancreatic ductal adenocarcinoma carries a five-year survival rate of roughly twelve percent and is projected to become the second most common cause of cancer-related death within the next decade. More than ninety percent of cases are driven by mutations in the KRAS gene, and most tumours arise from tiny precancerous growths called pancreatic intraepithelial neoplasias, which are too small to detect on imaging scans.

How It Works

The Penn team used two compounds developed by Revolution Medicines that target different forms of the KRAS mutation. When mice were treated after precancerous lesions had formed but before tumours appeared, the lesions were markedly reduced within twenty-eight days. Long-term treatment resulted in median survival exceeding one year, compared to fewer than five months in untreated animals. Three-dimensional mapping confirmed that normal pancreatic tissue remained undamaged.

What Comes Next

The researchers plan to launch clinical trials in high-risk patients who are already being monitored for pancreatic cysts, including those with BRCA1, BRCA2, or PALB2 gene mutations and hereditary pancreatitis. Revolution Medicines already has related drugs in advanced clinical development for treating established cancers, with multiple Phase three trials planned for twenty twenty-six.